Latest News

  • 2025
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • Earlier
December 17, 2019
Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of AKST4290 on Choroidal Blood Flow in Age-Related Macular Degeneration
December 9, 2019
Alkahest Presents Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease
December 5, 2019
Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference
October 8, 2019
Alkahest Announces Multiple Presentations at the Society for Neuroscience Annual Meeting
August 19, 2019
Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of Postoperative Recovery Following Primary Hip or Knee Arthroplasty
August 5, 2019
Alkahest Announces Positive Top-line Data from Phase 2 Study in Mild to Moderate Alzheimer’s Disease
July 29, 2019
Alkahest Phase 2a Study AKST4290-202 in Refractory Neovascular AMD meets Primary and Secondary Endpoints
July 24, 2019
Alkahest Strengthens Executive Leadership with Appointment of Robert Klein as Chief Business Officer
July 15, 2019
Alkahest to Present New Data from Phase 2a Study of AKST4290 in Refractory Neovascular AMD at the 2019 American Society of Retina Specialists Annual Meeting
March 26, 2019
Alkahest to Present Data in Alzheimer’s and Parkinson’s Diseases at the AD/PD Conference
March 25, 2019
Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress
March 18, 2019
Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer’s Disease
March 14, 2019
Alkahest to Present Results from Phase 2a Open Label Study of AKST4290 in wet AMD at Retina World Congress
December 17, 2018
Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration
December 4, 2018
Alkahest Doses First Subject in Phase 2 Clinical Trial of GRF6021 in Patients with Parkinson’s Disease and Cognitive Impairment
November 7, 2018
Alkahest Appoints Elizabeth Jeffords as Chief Commercial and Strategy Officer
November 5, 2018
Alkahest to Present at the Society for Neuroscience Annual Meeting
November 2, 2018
Alkahest Scientific Founder Tony Wyss-Coray Recognized as One of TIME Magazine’s 50 Most Influential People in Health Care
October 29, 2018
Alkahest Presentation at Clinical Trials in Alzheimer’s Disease (CTAD) Conference October 26, 2018, Barcelona, Spain
August 1, 2018
Alkahest, Inc. Announces Key Appointment
July 23, 2018
Alkahest to Present at Alzheimer’s Association International Conference (AAIC) Annual Meeting July 22-26, 2018 Chicago, IL
June 18, 2018
Alkahest, Inc. Announces Key Appointment
May 21, 2018
Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 for Parkinson’s Disease
May 14, 2018
Alkahest Announces Initiation of Two Phase 2 Clinical Trials of ALK4290 in Age-Related Macular Degeneration
April 25, 2018
Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer’s Disease
February 12, 2018
Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support the Clinical Development of a Novel Parkinson’s Therapy
January 23, 2018
Alkahest, Inc. Announces Key Appointments